BROAD

Empress Therapeutics Appoints Dawn Thompson, Ph.D., Senior Vice President, Head of Platform Development

Retrieved on: 
Wednesday, August 16, 2023
Health, Technology, Genetics, Research, Artificial Intelligence, Science, DNA, Broad Institute, Microbiology, Therapy, Senior, University, Harvard University, Electronics, Head, RNA-Seq, Agriculture, Genomics, Automation, Genetic code, Associate, Chemistry, Publication, Flagship Pioneering, Engineering, Emperor, Biology, Entrepreneurship, AI, Ginkgo, Next Generation, University of New Hampshire, Synthetic biology, Antibiotics

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Dawn Thompson, Ph.D., has been appointed Senior Vice President, Head of Platform Development.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Dawn Thompson, Ph.D., has been appointed Senior Vice President, Head of Platform Development.
  • At Gingko, she also oversaw platform development for engineering of novel organism factories to deliver products across diverse commercial applications and markets including pharmaceuticals, living medicines, agriculture, and electronics.
  • At the Broad, Dr. Thompson was concurrently a Senior Group Leader in Evolutionary Genomics.
  • Dr. Thompson was a postdoctoral fellow at Harvard University and received her Ph.D. from the University of Oregon and her B.S.

Janet Hanson to be Honored with Lifetime Achievement Award at Ellevate's Mobilize Women Awards and Cocktail Reception

Retrieved on: 
Friday, May 19, 2023
ABA, International Woman's Flag Football Association, NFP, Goldman, Culture, University, Diageo, Ellevate Network, Royal Bank of Canada, Goldman Sachs, Satyn (magazine), Gerald Loeb Lifetime Achievement Award winners, DTCC, Growth, SunCommon, Courage, Summit, Accenture, Nightclub, Interior design, Entertainment, New York Life Insurance Company, Woman

NEW YORK, May 19, 2023 /PRNewswire-PRWeb/ -- Ellevate Network, the largest community of women+ at work, is excited to announce that Janet Hanson will be an honoree at the Mobilize Women Cocktail Reception on June 6th at Prince George Ballroom in New York City.

Key Points: 
  • NEW YORK, May 19, 2023 /PRNewswire-PRWeb/ -- Ellevate Network, the largest community of women+ at work, is excited to announce that Janet Hanson will be an honoree at the Mobilize Women Cocktail Reception on June 6th at Prince George Ballroom in New York City.
  • "I am honored and delighted to accept the Ellevate Lifetime Achievement Award," said Hanson.
  • "We're thrilled to honor Janet Hanson with the Lifetime Achievement Award at this year's Mobilize Women," said Maricella Hererra, CEO of Ellevate Network.
  • If you'd like to attend the Mobilize Women Awards and Cocktail Reception, you can purchase your tickets here or email [email protected] to reserve a table..

PacBio To Begin Commercial Shipment of Revio Systems

Retrieved on: 
Tuesday, March 7, 2023
Genome, Apple IIe, Human genome, Biotechnology, Translational Genomics Research Institute, Wellcome Sanger Institute, Breeding, Genetics, Research, Human, High fidelity, Human Genome Project, DNA, Washington University in St. Louis, Health, Disease, Baylor College of Medicine, MIT, Biology, De novo, Methylation, Genomics, Outline of health sciences, Associate, Broad Institute, Harvard University, Agriculture, Pharmaceutical industry, Antibiotics, Abraxis BioScience

MENLO PARK, Calif., March 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023. As previously announced, the Revio system features significant advances in SMRT Cell design, compute, and system architecture. Together, this enables a dramatic increase in throughput and lower sequencing costs with the trusted power of HiFi chemistry, which offers exceptional accuracy and direct methylation detection.

Key Points: 
  • Broad is one of many customers to purchase multiple systems, ordering ten Revio systems to scale long-read sequencing for population sequencing initiatives.
  • The ten Revio systems at Broad will have the same sequencing capacity as 150 Sequel IIe systems.
  • PacBio announced orders of 76 Revio systems in the quarter ended December 31, 2022, making it the most successful product announcement in PacBio's history.
  • PacBio expects to ship at least 25 Revio systems during the first quarter of 2023 and will continue to scale throughout the year.

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

Retrieved on: 
Wednesday, January 4, 2023
Internal medicine, Bayer, Lymphatic system, Patient, University, CLEC2D, Biotechnology, Dana–Farber Cancer Institute, Investment, Drug development, Tulane University School of Medicine, MGH, NK, Safety, Lymphoma, FC, Regeneron Pharmaceuticals, Immunoglobulin G, Multimedia, Therapy, Sarah Cannon Research Institute, Principal, Lung cancer, Drug, Eli Lilly, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, Research, CD161, Cancer, Acquisition, Machine learning, Oncology, MIT, Pharmaceutical industry

WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the first patient has been dosed in a Phase 1/2a clinical trial evaluating use of novel cancer immunotherapeutic IMT-009 in solid tumors and hematologic malignancies. The company also announced the addition of James Wooldridge, M.D., to their Clinical Advisory Board.

Key Points: 
  • We look forward to further investigation of IMT-009 and its potential for patients awaiting improved treatment options."
  • The trial will subsequently transition into Phase 2 to assess the safety and efficacy of IMT-009 as a monotherapy and in combination with another anticancer agent.
  • The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as well as identify the Recommended Phase 2 Dose (RP2D).
  • Immunitas is a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated treatments for patients with cancer.

Immunitas Therapeutics to Present Preclinical Data on IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Doctor of Philosophy, Therapy, National Autonomous University of Mexico, Bayer, MGH, IND, Recommended exposure limit, Machine learning, Investment, SITC, University of Buenos Aires, Diversity, Neoplasm, Patient, B cell, Committee, Research, NIH, NIH Director's New Innovator Award, Annual general meeting, Multimedia, Immunotherapy, Community, Stanford University School of Medicine, CD161, Coronavirus Scientific Advisory Board (Turkey), Cancer, New, Company, National Autonomous University, Department, Society, Biomedical sciences, Dana–Farber Cancer Institute, Rockefeller University, CLEC2D, MIT, Safety, Physiology, NK, Lymphatic system, Society for Immunotherapy of Cancer, View, Pharmaceutical industry, Vaccine, Online gambling, Immunology, Biology

WALTHAM, Mass., Oct. 5, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced they will present preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held both virtually and in Boston from November 8-12, 2022. The company also announced the addition of Juliana Idoyaga, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • The SITC presentation will demonstrate the potential of IMT-009 as a novel cancer immunotherapy to treat solid tumors and hematological malignancies.
  • Poster Presentation Details for IMT-009:
    Date/Time:All poster presentations are made available by the conference on November 10, 2022.
  • The SITC poster presentation will be available on the Immunitas Therapeutics website on November 10, 2022.
  • Immunitas is a precision immunotherapy company committed to discovering and developing novel, differentiated treatments for patients with cancer.

Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies

Retrieved on: 
Wednesday, September 21, 2022
Therapy, Safety, CD161, Machine learning, FDA, Food, MIT, IND, Recommender system, Bayer, Investment, Computational biology, NK, Patient, Dana–Farber Cancer Institute, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Clinical trial, CLEC2D, Lymphatic system, Investigational New Drug, MGH, Multimedia, View, Pharmaceutical industry

WALTHAM, Mass., Sept. 21, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as well as identify the Recommended Phase 2 Dose (RP2D). The trial will then transition into Phase 2 with multiple expansion cohorts to assess the safety and efficacy of IMT-009 alone or in combination with another antineoplastic agent.

Key Points: 
  • "We are thrilled to advance IMT-009 to the clinic as we believe it represents a new wave of immuno-oncology agents with transformative potential in both hematological malignancies and solid tumors," said Seng-Lai "Thomas" Tan, Ph.D., Chief Scientific Officer of Immunitas Therapeutics.
  • "IMT-009 is a first-in-class therapeutic with exciting potential for efficacy in a broad range of tumor types.
  • I applaud the team at Immunitas that has driven it forward, and our academic founders who originally identified CD161 as an inhibitory T-cell target.
  • Immunitas is a precision immunotherapy company committed to discovering and developing novel, differentiated treatments for patients with cancer.

Broad Institute Partners with Datavant to Scale Clinico-Genomic Research by Connecting Health Data

Retrieved on: 
Monday, September 12, 2022
Health, Public sector, Registry, Privacy, Organization, MIT, Gene, Public, Heart failure, Social media, Harvard University, Patient, Roger Hawkins (drummer), SAN, Research, Friction, GLOBE, Hospital, Mortality, Broad Institute, Genome, Disease, Whole genome sequencing, Mobile phone, Medical imaging, Pharmaceutical industry

SAN FRANCISCO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Broad Institute of MIT and Harvard (Broad), a leader in advancing human health through genomic research, and Datavant, the leader in helping organizations securely connect health data, today announce a long-term collaboration to scale clinico-genomic registries across rare and common diseases with unmet medical needs.

Key Points: 
  • SAN FRANCISCO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Broad Institute of MIT and Harvard (Broad), a leader in advancing human health through genomic research, and Datavant, the leader in helping organizations securely connect health data, today announce a long-term collaboration to scale clinico-genomic registries across rare and common diseases with unmet medical needs.
  • Broad has built a novel direct-to-patient research platform that enables researchers to directly engage patients in genomic research.
  • Researchers can contact patients via social media platforms and other digital channels to recruit and consent those patients into studies.
  • Historically genomic research is a bespoke fragmented effort that is stymied by cost barriers and data connectivity challenges.

Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer

Retrieved on: 
Wednesday, July 13, 2022
Knowledge, NK, Dana–Farber Cancer Institute, Sale, Corporation, Boston University School of Law, Leadership, Multimedia, Boston University, Therapy, Investment, View, Patient, Law, Vertex Pharmaceuticals, CD161, Machine learning, Lymphatic system, MGH, MIT, Bayer, Cancer, Industry, Management, Pharmaceutical industry

WALTHAM, Mass., July 13, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of Lynette Herscha, J.D., as Chief Operating Officer. Ms. Herscha is a seasoned biopharma executive with extensive experience developing and implementing legal and operational strategies to enable company growth and success. She joins the Immunitas team from Senda Biosciences, where she most recently served as Chief Legal Officer and Corporate Secretary.

Key Points: 
  • Bolsters executive leadership team with industry expert, bringing a deep knowledge of pharmaceutical operations strategy
    WALTHAM, Mass., July 13, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of Lynette Herscha, J.D., as Chief Operating Officer.
  • While at Concert Pharmaceuticals, current Immunitas President and Chief Executive Officer Amanda Wagner and Ms. Herscha collaborated on the successful closing of a $250 million asset sale to Vertex Pharmaceuticals.
  • "We are delighted to welcome Lynette to the Immunitas executive team as the company's first Chief Operating Officer," said Amanda Wagner, M.B.A., Chief Executive Officer of Immunitas Therapeutics.
  • As the company approaches the clinic, Immunitas is at a compelling inflection point where operational excellence can be incredibly impactful," said Ms. Herscha.

FINN Partners Promotes Peter Hahn to Lead the Agency's new Brand Innovation and Transformation Practice

Retrieved on: 
Tuesday, April 5, 2022
EDS, Face, JPMorgan Chase, Marketing, NSTA, Growth, Carnegie, Partnership, CEO, Health, Philosophy, Technology, Pfizer, Twitter, Public relations, Foundation, IEEE, Kellogg, ACS, Nestlé, AOL, Instagram, Acquisition, Sales, Titan

NEW YORK, April 5, 2022 /PRNewswire/ -- Global independent marketing and communications firm FINN Partners announced today that it has promoted Peter Hahn to Brand Innovation and Transformation Practice Leader.

Key Points: 
  • NEW YORK, April 5, 2022 /PRNewswire/ -- Global independent marketing and communications firm FINN Partners announced today that it has promoted Peter Hahn to Brand Innovation and Transformation Practice Leader.
  • FINN created this new Practice in response to increasing client demand for brand and business consulting services in the face of rapid digital transformation.
  • Hahn is based out of FINN's Washington D.C. office and will continue to report to Matt Bostrom, Managing Partner, Integrated Marketing.
  • FINN Partners clients are also supported through longstanding partner agencies and its membership in the PROI network of leading agencies around the world.

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Retrieved on: 
Monday, February 28, 2022
GLOBE, Cell, Patent, Editas Medicine, United States Court of Appeals for the Federal Circuit, Security (finance), CRISPR, Annual report, Genome, Company, Eukaryote, Clinical trial, USPTO, U.S. Securities and Exchange Commission, U.S. Patent No. 1, CVC, DNA, Private Securities Litigation Reform Act, Nasdaq, Emmanuelle, Technology, Cas9, University of California, University of Vienna, Gene editing, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leadinggenome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to theBroad Institute, Inc.(Broad) involving specific patents for CRISPR/Cas9 editing in human cells.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leadinggenome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to theBroad Institute, Inc.(Broad) involving specific patents for CRISPR/Cas9 editing in human cells.
  • Pending an appeal to the Federal Circuit, this decision ends the U.S. patent interference between theUniversity of California, theUniversity of Vienna, and Emmanuelle Charpentier (collectively, CVC)and Broad.
  • The patents at issue in the current interference are owned by Broad and exclusively licensed to Editas Medicine for the development of medicines for people living with serious diseases.
  • Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.